Professor of Medical Oncology and Director, Centre Leon Berard, EURACAN ERN LYRICAN, President, Unicancer
President, French Society of Nuclear Medicine and Professor of Medicine Toulouse University Institute of Cancer - Oncopole
Nuclear Safety and Security at the
Associate Professor of Nuclear Medicine, Department of Medicine and Surgery University of Milan Bicocca and President Elect, European Association of Nuclear Medicine (EANM)
Department of Nuclear Medicine at the University of Zurich
International Neuroendocrine Cancer Alliance (INCA) Representative and Patient Engagement, Education & Policy Lead, Neuroendocrine Cancer UK
Professor Emeritus, Economics Stockholm School of Economics
Head of Policy at the European Cancer
Global Director, RLT Policy Strategy Novartis
Hybrid event on 11 April 2024
European Parliament, Brussels ● Room JAN6Q1
In-person and virtual
This event will take place in the Central European time zone
Radioligand therapy (RLTs) is emerging as an essential pillar in cancer care and is a targeted treatment approach that has shown great value in gastroenteropancreatic neuroendocrine tumors and prostate cancer. It is also being researched as a promising treatment modality for several other advanced cancers. The scientific innovation on radioligand therapies is progressing rapidly, however, the healthcare system readiness for this modality is lagging. With the patient demand anticipated to increase, there is a critical and urgent need to enhance the understanding of the current level of readiness for RLT across countries, and to address issues impacting this readiness, to ensure that the appropriate patients receive this treatment in a timely and equitable manner.
IQVIA conducted research in 2023 using discussions and workshops with industry professionals with the aim to scope out these levers and begin identifying the capacity for RLTs in different European countries.
On behalf of MEP Niels Geuking (EPP, Germany), please join us in person or virtually for this public working session on preparing European infrastructure and healthcare systems for the latest advances in cancer care, hosted within the European Parliament in Brussels. This event is organized by the IQVIA Institute for Human Data Science with funding from Novartis.
.svg){kind=icon}
